Compositions for expanding regulatory T cells (Treg), and treating autoimmune and inflammatory diseases and conditions
View Patent ↗In alternative embodiments, provided are compositions, including e.g., isolated, synthetic or recombinant peptides or polypeptides, for: expanding regulatory T cells (Treg) populations; or, for treating, ameliorating, preventing or reversing a vascular inflammation, and Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities and the same or similar types of acute or chronic vascular inflammatory abnormalities, and methods for making and using them. In one embodiment, provided are immunotherapies for promoting expansion of natural, regulatory T cells to establish, or re-establish, vascular homeostasis; or, for treating, reversing, preventing or ameliorating: a disease or condition associated with an autoimmune disease or condition; an immune-mediated vascular disorder; a disease or condition that is currently treated with intravenous immunoglobulin (IVIG) therapy; a vascular coronary abnormality; an acute or a chronic vasculitis; an autoimmune inflammatory vasculitis; a T cell mediated pediatric vasculitis; Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries; atherosclerosis; rheumatoid arthritis or Juvenile Idiopathic Arthritis; an autoimmune disease or condition; or, a neoplastic hematological disorder such as a lymphoma (e.g., a T cell lymphoma) or a leukemia.
1. A therapeutic composition comprising:
a combination of isolated, synthetic or recombinant peptides or polypeptides comprising:
(SEQ ID NO: 1)
TAALGCLVKDYFPEP;
(SEQ ID NO: 9)
TFPAVLQSSGLYSLS;
(SEQ ID NO: 11)
LYSLSSVVTVPSSSL;
(SEQ ID NO: 14)
TYRVVSVLTVLHQDW;
(SEQ ID NO: 45)
SVLTVLHQDWLNGKE;
(SEQ ID NO: 8)
NNYKTTPPVLDSDGS;
(SEQ ID NO: 16)
QGNVFSCSVMHEALH;
and
(SEQ ID NO: 17)
SCSVMHEALHNHYTQ.
2. The therapeutic composition of claim 1 , wherein the combination of isolated, synthetic or recombinant peptides or polypeptides is formulated for administration:
via an enteral or a parenteral route, or orally, subcutaneously, or systemically or topically;
via a parenteral route comprising a subcutaneous, an intravenous (IV), an intradermal, an intramuscular, an intraperitoneal, an intranasal, a transdermal or a buccal route;
intradermally as a sterile formulation; or
as a controlled release formulation, or formulated in a tablet, a pill, a gel, a patch, in an implant or in a spray, as an inhaled powder.
3. The therapeutic composition of claim 1 , wherein the combination of isolated, synthetic or recombinant peptides or polypeptides is formulated for administration:
parenterally by one bolus injection, or by two, three or four or more bolus injections, or by gradual perfusion over time;
at intervals of 1 week, 2 weeks, 4 weeks (or one month), 6 weeks, 8 weeks or one year; or
at a daily dose of peptide in a range of about 10 nanograms to 10 milligrams, or about 1 microgram to 10 milligrams.
4. The therapeutic composition of claim 1 , wherein any one of the isolated, synthetic or recombinant peptide or polypeptide of the combination of isolated, synthetic or recombinant peptides or polypeptides has at least one conservative amino acid substitution and retains its property of generating natural regulatory T cells (nTregs) that can suppress pro-inflammatory T cells and pro-inflammatory T cell responses when administered to an individual.
5. The therapeutic composition of claim 4 , wherein the at least one conservative amino acid substitution comprises:
substituting an amino acid with another amino acid of like characteristics; or,
a replacement of an aliphatic amino acid with another aliphatic amino acid;
a replacement of a Serine with a Threonine or vice versa;
a replacement of an acidic residue with another acidic residue;
a replacement of a residue bearing an amide group with another residue bearing an amide group;
an exchange of a basic residue with another basic residue; or
a replacement of an aromatic residue with another aromatic residue,
and optionally the peptide or polypeptide, or at least one amino acid in the peptide or polypeptide, comprises or consists of a peptidomimetic or a non-natural amino acid residue.
6. The therapeutic composition of claim 1 , wherein any one of the isolated, synthetic or recombinant peptides or polypeptides of the combination of isolated; synthetic or recombinant peptides or polypeptides is formulated as a pharmaceutical composition or a formulation,
and optionally the pharmaceutical composition or formulation comprises a pharmaceutically acceptable excipient.
7. The therapeutic composition of claim 1 , wherein any one of the isolated, synthetic or recombinant peptides or polypeptides of the combination of isolated, synthetic or recombinant peptides or polypeptides is formulated in a sterile solution for injection, or as a powder or a lyophilized or a freeze-dried composition.
8. The therapeutic composition of claim 1 , wherein any one of the polypeptide or peptides or polypeptides of the combination of isolated, synthetic or recombinant peptides or polypeptides is formulated in or as a liposome or a nanoparticle.
9. The therapeutic composition of claim 1 , wherein any one of the polypeptide or peptides or polypeptides of the combination of isolated, synthetic or recombinant peptides or polypeptides is formulated in or as a vaccine.
10. The therapeutic composition of claim 1 , wherein the combination of isolated, synthetic or recombinant peptides or polypeptides consists of:
(SEQ ID NO: 1)
TAALGCLVKDYFPEP;
(SEQ ID NO: 9)
TFPAVLQSSGLYSLS;
(SEQ ID NO: 11)
LYSLSSVVTVPSSSL;
(SEQ ID NO: 14)
TYRVVSVLTVLHQDW;
(SEQ ID NO: 45)
SVLTVLHQDWLNGKE;
(SEQ ID NO: 8)
NNYKTTPPVLDSDGS;
(SEQ ID NO: 16)
QGNVFSCSVMHEALH;
and,
(SEQ ID NO: 17)
SCSVMHEALHNHYTQ.
11. The therapeutic composition of claim 1 , wherein the combination of isolated, synthetic or recombinant peptides or polypeptides is formulated for administration as a vaccine with an adjuvant.
12. The therapeutic composition of claim 1 , wherein the combination of isolated, synthetic or recombinant peptides or polypeptides consists essentially of:
(SEQ ID NO: 1)
TAALGCLVKDYFPEP;
(SEQ ID NO: 9)
TFPAVLQSSGLYSLS;
(SEQ ID NO: 11)
LYSLSSVVTVPSSSL;
(SEQ ID NO. 14)
TYRVVSVLTVLHQDW;
(SEQ ID NO: 45)
SVLTVLHQDWLNGKE;
(SEQ ID NO: 8)
NNYKTTPPVLDSDGS;
(SEQ ID NO: 16)
QGNVFSCSVMHEALH;
and,
(SEQ ID NO: 17)
SCSVMHEALHNHYTQ.